Understanding the Market | CF PHARMTECH rose nearly 3% before noon as the company's minimally invasive intervention device for treating emphysema completed its first enrollment
I'm PortAI, I can summarize articles.
CF PHARMTECH's stock price rose nearly 3% before noon, reaching HKD 29.2, with a transaction volume of HKD 5.3645 million. The company announced that its self-developed bronchial valve lung volume reduction device successfully completed the enrollment of its first subject, marking the beginning of the clinical validation phase, aimed at providing minimally invasive treatment options for patients with emphysema and other chronic obstructive pulmonary diseases. The study will evaluate the safety and technical success rate of the device and observe changes in key clinical outcomes
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments